This clinical trial is focused on studying a type of lung cancer known as Non-small Cell Lung Cancer (NSCLC) that has a specific mutation called EGFR-mutated. The study is comparing a new treatment called MK-2870 with a standard chemotherapy treatment known as platinum-based doublet chemotherapy. The chemotherapy includes drugs like carboplatin and pemetrexed, which are commonly used to treat this type of cancer. The purpose of the study is to see how well MK-2870 works compared to the standard chemotherapy in terms of how long patients live without the cancer getting worse and overall survival.

Participants in the study will receive either MK-2870 or the standard chemotherapy. MK-2870 is given as an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The study will last for a period of up to 72 weeks, during which the effects of the treatments will be monitored. The study will also look at other aspects such as the response rate to the treatment, the duration of the response, and changes in quality of life related to symptoms like cough and chest pain.

In addition to MK-2870 and the chemotherapy drugs, other medications may be used in the study, including H2-Receptor antagonists, glucocorticoids, antihistamines, and a combination of buclizine hydrochloride, paracetamol, and codeine phosphate. These medications are used to manage side effects or other conditions that may arise during the treatment. The study aims to provide valuable information on the effectiveness and safety of MK-2870 compared to the current standard treatment for patients with this type of lung cancer.